{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T05:28:23Z","timestamp":1782624503957,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,4,20]],"date-time":"2013-04-20T00:00:00Z","timestamp":1366416000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s40265-013-0052-0","type":"journal-article","created":{"date-parts":[[2013,4,19]],"date-time":"2013-04-19T07:06:53Z","timestamp":1366355213000},"page":"563-574","source":"Crossref","is-referenced-by-count":29,"title":["Pasireotide: A Review of Its Use in Cushing\u2019s Disease"],"prefix":"10.1007","volume":"73","author":[{"given":"Kate","family":"McKeage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,20]]},"reference":[{"issue":"7","key":"52_CR1","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BM Biller","year":"2008","unstructured":"Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93(7):2454\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"52_CR2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-11-1095","volume":"167","author":"RA Feelders","year":"2012","unstructured":"Feelders RA, Pulgar SJ, Kempel A, et al. The burden of Cushing\u2019s disease: clinical and health-related quality of life aspects. Eur J Endocrinol. 2012;167(3):311\u201326.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"52_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1210\/jc.86.1.117","volume":"86","author":"J Lindholm","year":"2001","unstructured":"Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of Cushing\u2019s syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86(1):117\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"52_CR4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.diabet.2012.10.005","volume":"39","author":"Y Reznik","year":"2013","unstructured":"Reznik Y, Bertherat J, Borson-Chazot F, et al. Management of hyperglycaemia in Cushing\u2019s disease: expert\u2019s proposals on the use of pasireotide. Diabetes Metab. 2013;39(1):34\u201341.","journal-title":"Diabetes Metab"},{"issue":"4","key":"52_CR5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","volume":"40","author":"J Etxabe","year":"1994","unstructured":"Etxabe J, Vazquez JA. Morbidity and mortality in Cushing\u2019s disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994;40(4):479\u201384.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"52_CR6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1210\/jc.2007-2013","volume":"93","author":"CG Patil","year":"2008","unstructured":"Patil CG, Prevedello DM, Lad SP, et al. Late recurrences of Cushing\u2019s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab. 2008;93(2):358\u201362.","journal-title":"J Clin Endocrinol Metab"},{"key":"52_CR7","doi-asserted-by":"crossref","unstructured":"Arnaldi G, Boscaro M. New treatment guidelines on Cushing\u2019s disease. F1000 Med Rep. 2009. doi: 10.3410\/M1-64 .","DOI":"10.3410\/M1-64"},{"issue":"4","key":"52_CR8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","volume":"152","author":"LJ Hofland","year":"2005","unstructured":"Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005;152(4):645\u201354.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"52_CR9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.17925\/EE.2012.08.02.99","volume":"8","author":"A Lacroix","year":"2012","unstructured":"Lacroix A, Pivonello R. Medical treatment of Cushing\u2019s disease with pasireotide. Eur Endocrinol. 2012;8(2):99\u2013104.","journal-title":"Eur Endocrinol"},{"key":"52_CR10","unstructured":"European Medicines Agency. Signifor solution for injection: summary of product characteristics. 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002052\/WC500128056.pdf . Accessed 9 Jan 2013."},{"key":"52_CR11","unstructured":"Novartis Pharmaceuticals Corporation. Signifor: full prescribing information. 2012. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/signifor.pdf . Accessed 12 Jan 2013."},{"issue":"11","key":"52_CR12","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","volume":"91","author":"DL Batista","year":"2006","unstructured":"Batista DL, Zhang X, Gejman R, et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab. 2006;91(11):4482\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"52_CR13","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12020-012-9668-1","volume":"42","author":"C Beglinger","year":"2012","unstructured":"Beglinger C, Hu K, Wang Y, et al. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, phase I study. Endocrine. 2012;42(2):366\u201374.","journal-title":"Endocrine"},{"key":"52_CR14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/DDDT.S29125","volume":"6","author":"G Golor","year":"2012","unstructured":"Golor G, Hu K, Ruffin M, et al. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther. 2012;6:71\u20139.","journal-title":"Drug Des Devel Ther"},{"key":"52_CR15","doi-asserted-by":"crossref","unstructured":"Shenouda M, Maldonado M, Wang Y, et al. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels. Am J Ther. 2012. doi: 10.1097\/MJT.0b013e31824c3eb4 .","DOI":"10.1097\/MJT.0b013e31824c3eb4"},{"key":"52_CR16","unstructured":"Henry RR, Mudaliar S, Wetli-Hermosillo K, et al. Mechanism and management of hyperglycaemia associated with pasireotide: results from studies in healthy volunteers [abstract no. P260]. European Congress of Endocrinology; 30 Apr 4\u2013May 2011; Rotterdam."},{"issue":"19","key":"52_CR17","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","volume":"362","author":"RA Feelders","year":"2010","unstructured":"Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease. N Engl J Med. 2010;362(19):1846\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"52_CR18","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1210\/jc.2011-2753","volume":"97","author":"R Pas van der","year":"2012","unstructured":"van der Pas R, de Bruin C, Leebeek FWG, et al. The hypercoagulable state in Cushing\u2019s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab. 2012;97(4):1303\u201310.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"52_CR19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/0091270011400072","volume":"52","author":"Y Horsmans","year":"2012","unstructured":"Horsmans Y, Hu K, Ruffin M, et al. Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study. J Clin Pharmacol. 2012;52(4):552\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"52_CR20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115\u201322.","journal-title":"J Clin Endocrinol Metab"},{"key":"52_CR21","doi-asserted-by":"crossref","unstructured":"Boscaro M, Zhang Y, Sen K, et al. Long-term treatment of Cushing\u2019s disease with pasireotide (SOM230): results from a Phase II extension study [abstract no. P640]. European Congress of Endocrinology, Prague, 24\u201328 Apr 2010.","DOI":"10.1210\/endo-meetings.2010.PART1.P6.P1-274"},{"issue":"10","key":"52_CR22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med. 2012;366(10):914\u201324.","journal-title":"N Engl J Med"},{"key":"52_CR23","unstructured":"Bertherat J, Schopohl J, Ludlam WH, et al. Long-term pasireotide use leads to significant and sustained improvements in the signs and symptoms of Cushing disease: 24-month results from a randomized phase III study [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23\u201326 Jun 2012."},{"key":"52_CR24","unstructured":"Lacroix A, Ludlam W, Mantero F, et al. Initial response to pasireotide treatment is predictive of 12-month response: results of a large, randomized, double-blind, phase III study in patients with Cushing disease [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23\u201326 Jun 2012."},{"key":"52_CR25","unstructured":"Schopohl J, Bertherat J, Ludlam W, et al. Long-term pasireotide use leads to improvements in the biochemical parameters of Cushing\u2019s disease: 24-month results from a randomized phase III study [abstract no. P1410]. In: 15th International Congress of Endocrinology and 14th European Congress of Endocrinology, Florence, 5\u20139 May 2012."},{"key":"52_CR26","unstructured":"Pivonello R, Petersenn S, Newell-Price J, et al. Pasireotide treatment in Cushing disease is associated with significant improvements in hypertension: 12-month results from a large phase III study [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23\u201326 Jun 2012."},{"key":"52_CR27","unstructured":"Gadelha M, Badia X, Zgliczynski W, et al. Pasireotide treatment is associated with clinically meaningful improvements in health-related quality of life in Cushing disease: results from a large, randomized, double-blind, phase III trial [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23\u201326 Jun 2012."},{"key":"52_CR28","unstructured":"Bertherat J, Ludlam WH, Pivonello R, et al. Pasireotide as a long-term treatment for patients with Cushing disease: 24-month safety results from a randomized phase III study [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23\u201326 Jun 2012."},{"issue":"3","key":"52_CR29","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11102-012-0397-5","volume":"15","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Petersenn S. Medical management of Cushing\u2019s disease: what is the future? Pituitary. 2012;15(3):330\u201341.","journal-title":"Pituitary"},{"key":"52_CR30","doi-asserted-by":"crossref","unstructured":"Trementino L, Cardinaletti M, Concettoni C, et al. Long-term efficacy of pasireotide in a patients with Cushing\u2019s disease and diabetes: results in the short term are not always predictive of long-term response [abstract no. P108]. J Clin Endokrinol Stoffw. 2012;5(Special Issue 3).","DOI":"10.1530\/endoabs.32.P45"},{"issue":"22","key":"52_CR31","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMc1204078","volume":"366","author":"R Libe","year":"2012","unstructured":"Libe R, Groussin L, Bertherat J. Pasireotide in Cushing\u2019s disease [letter]. N Engl J Med. 2012;366(22):2134.","journal-title":"N Engl J Med"},{"key":"52_CR32","unstructured":"Ning G, Wang W, Maldonado M, et al. Long-term efficacy and safety of pasireotide in Cushing\u2019s disease: a 36-month case report [abstract no. P353]. In: 15th International Congress of Endocrinology and 14th European Congress of Endocrinology, Florence, 5\u20139 May 2012."},{"issue":"2","key":"52_CR33","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1210\/jc.2012-3126","volume":"98","author":"RA Feelders","year":"2013","unstructured":"Feelders RA, Hofland LJ. Medical treatment of Cushing\u2019s disease. J Clin Endocrinol Metab. 2013;98(2):425\u201338.","journal-title":"J Clin Endocrinol Metab"},{"key":"52_CR34","unstructured":"Ligueros-Saylan M, Zhang Y, Newell-Price J, et al. Evaluation of the efficacy and safety of pasireotide LAR in patients with mild-to-moderate Cushing\u2019s disease: a randomized, double-blind, multicentre, phase III study design [abstract no. P1542.1]. In: 15th International Congress of Endocrinology and 14th European Congress of Endocrinology, Florence, 5\u20139 May 2012."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0052-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0052-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0052-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T17:11:15Z","timestamp":1562951475000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0052-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,20]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0052-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,20]]}}}